NAMS NewAmsterdam Pharma Company N.V.
Healthcare$36.11+1.89%ClosedMarket Cap: $4.22B
As of 2026-05-26
Analyst Consensus
Consensus
Buy
Target (Consensus)
$46.00
Target (Median)
$46.00
Target Range
$37.00 - $55.00
Upside from current price: 27.4%
Rating Distribution
3 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell
Recent Analyst Ratings
| Date | Firm | Action | Rating | Previous |
|---|---|---|---|---|
| 2026-02-19 | Guggenheim | maintain | Buy | Buy |
| 2026-02-18 | Needham | maintain | Buy | Buy |
| 2026-01-21 | RBC Capital | maintain | Outperform | Outperform |
| 2025-12-16 | Stifel | maintain | Buy | Buy |
| 2025-12-02 | Goldman Sachs | maintain | Neutral | Neutral |
| 2025-11-06 | RBC Capital | maintain | Outperform | Outperform |
| 2025-11-05 | Needham | maintain | Buy | Buy |
| 2025-10-17 | Citigroup | maintain | Buy | Buy |
| 2025-08-07 | RBC Capital | maintain | Outperform | Outperform |
| 2025-06-12 | Needham | maintain | Buy | Buy |
Forward Estimates
| Period | EPS Est. | Revenue Est. | # Analysts |
|---|---|---|---|
| Fri Dec 31 | $-1.39 | $171.1M | 8 |
| Sun Dec 31 | $-0.27 | $422.7M | 7 |
| Mon Dec 31 | $1.51 | $796.4M | 6 |
| Tue Dec 31 | $3.21 | $1.14B | 6 |